- ICH GCP
- Registre américain des essais cliniques
- Essai clinique NCT00963768
A Safety, Tolerability, Pharmacokinetics, and Pharmacodynamics Study of JNJ-28431754 in Patients With Type 2 Diabetes Mellitus
22 avril 2014 mis à jour par: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.
A Double-Blind, Randomized, Placebo-Controlled Study to Evaluate the Safety, Tolerability, Pharmacokinetics and Pharmacodynamics of Single and Multiple Ascending Oral Doses of JNJ-28431754 in Type 2 Diabetes Mellitus Patients
The purpose of this study is to evaluate the safety, tolerability, pharmacokinetics (ie, blood levels of JNJ-28431754) and pharmacodynamics (ie, urine and blood levels of glucose) of JNJ-28431754 compared to placebo in patients with Type 2 diabetes mellitus.
Aperçu de l'étude
Statut
Complété
Les conditions
Intervention / Traitement
Description détaillée
This is a randomized (study drug assigned by chance), double-blind (neither physician, patient nor the sponsor knows the assigned treatment), placebo-controlled, single and multiple (14 days) ascending dose, parallel group study in 3 study centers (United States, Germany and South Korea).
Five cohorts (groups) of patients with Type 2 diabetes mellitus (T2DM) will be studied.
One dose level will be evaluated in each cohort.
Sixteen (16) patients will be randomly assigned to receive JNJ-28431754 and four (4) patients to receive matching placebo within each cohort.
The planned doses are 30, 100, 300 and 600 mg per day.
Twice-daily dosing may also be evaluated in one or more of the cohorts.
An additional cohort of Asian patients will also be evaluated at a dose level, which was previously tested in a prior cohort and considered to be well tolerated.
Blood and urine samples will be collected from patients during the study for pharmacokinetic and pharmacodynamic assessments.
The safety and tolerability of JNJ-28431754 will be monitored throughout the study.
Type d'étude
Interventionnel
Inscription (Réel)
116
Phase
- La phase 1
Contacts et emplacements
Cette section fournit les coordonnées de ceux qui mènent l'étude et des informations sur le lieu où cette étude est menée.
Lieux d'étude
-
-
-
Neuss, Allemagne
-
-
-
-
-
Seoul, Corée, République de
-
-
-
-
California
-
Chula Vista, California, États-Unis
-
-
Critères de participation
Les chercheurs recherchent des personnes qui correspondent à une certaine description, appelée critères d'éligibilité. Certains exemples de ces critères sont l'état de santé général d'une personne ou des traitements antérieurs.
Critère d'éligibilité
Âges éligibles pour étudier
25 ans à 65 ans (Adulte, Adulte plus âgé)
Accepte les volontaires sains
Non
Sexes éligibles pour l'étude
Tout
La description
Inclusion Criteria:
- Patients must have been diagnosed with Type 2 Diabetes for at least one year before screening
- Patients must be taking a stable dose of oral (by mouth) anti-diabetic monotherapy or a combination of two anti-diabetic medications
- Males or postmenopausal or surgically sterile women (post-menopausal is defined as no menses for at least 18 months prior to study start or no menses for 6 to 18 months)
- Body mass index (weight in kg/height in m2) should be between 20 to 39.9 kg/m2
Exclusion Criteria:
- History of Type 1, brittle diabetes or secondary forms of diabetes
- History of repeated severe hypoglycemic episodes
- History of diabetic complications including retinopathy, nephropathy, neuropathy, gastroparesis, or ketoacidosis
- History of, or currently active illness including but not limited to cardiovascular disease, hematological disease, respiratory disease, hepatic or gastrointestinal disease, endocrine/metabolic disorders, neurologic or psychiatric disease, or malignant neoplasms considered by the Investigator to be clinically significant
Plan d'étude
Cette section fournit des détails sur le plan d'étude, y compris la façon dont l'étude est conçue et ce que l'étude mesure.
Comment l'étude est-elle conçue ?
Détails de conception
- Objectif principal: Traitement
- Répartition: Randomisé
- Modèle interventionnel: Affectation parallèle
- Masquage: Quadruple
Armes et Interventions
Groupe de participants / Bras |
Intervention / Traitement |
---|---|
Expérimental: Cohort 1
JNJ-28431754 30 mg/day or placebo.
The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
|
A liquid suspension of 30 mg, 100 mg, 300 mg of JNJ-28431754 taken once (or twice) daily or 600 mg taken once daily will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser for 14 days (Day 1 and Days 3 through 16).
Autres noms:
A liquid suspension of placebo will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser once or twice daily for 14 days (Day 1 and Days 3 through 16).
|
Expérimental: Cohort 2
JNJ-28431754 100 mg/day or placebo.
The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
|
A liquid suspension of 30 mg, 100 mg, 300 mg of JNJ-28431754 taken once (or twice) daily or 600 mg taken once daily will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser for 14 days (Day 1 and Days 3 through 16).
Autres noms:
A liquid suspension of placebo will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser once or twice daily for 14 days (Day 1 and Days 3 through 16).
|
Expérimental: Cohort 3
JNJ-28431754 300 mg/day or placebo.
The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
|
A liquid suspension of 30 mg, 100 mg, 300 mg of JNJ-28431754 taken once (or twice) daily or 600 mg taken once daily will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser for 14 days (Day 1 and Days 3 through 16).
Autres noms:
A liquid suspension of placebo will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser once or twice daily for 14 days (Day 1 and Days 3 through 16).
|
Expérimental: Cohort 4
JNJ-28431754 600 mg/day or placebo.
The actual dose (mg) level selected for each cohort may be modified based on evaluation of preliminary safety, pharmacokinetic and pharmacodynamic data from previous cohorts.
|
A liquid suspension of 30 mg, 100 mg, 300 mg of JNJ-28431754 taken once (or twice) daily or 600 mg taken once daily will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser for 14 days (Day 1 and Days 3 through 16).
Autres noms:
A liquid suspension of placebo will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser once or twice daily for 14 days (Day 1 and Days 3 through 16).
|
Expérimental: Cohort 5
JNJ-28431754 at 30 mg/day, 100 mg/day, or 300 mg/day or placebo (the dose level to be determined from the prior cohort of patients tested and considered to be well tolerated).
|
A liquid suspension of 30 mg, 100 mg, 300 mg of JNJ-28431754 taken once (or twice) daily or 600 mg taken once daily will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser for 14 days (Day 1 and Days 3 through 16).
Autres noms:
A liquid suspension of placebo will be administered by study personnel directly into the patient's mouth using an oral liquid dispenser once or twice daily for 14 days (Day 1 and Days 3 through 16).
|
Que mesure l'étude ?
Principaux critères de jugement
Mesure des résultats |
Délai |
---|---|
The number of patients with adverse events as a measure of safety and tolerability
Délai: Up to 34 days (baseline [Day -1] through follow up [10 days following Day 22 visit])
|
Up to 34 days (baseline [Day -1] through follow up [10 days following Day 22 visit])
|
Mesures de résultats secondaires
Mesure des résultats |
Délai |
---|---|
Change from baseline (Day -1) for mean 24-hour plasma glucose concentration
Délai: Day -1 through Day 16
|
Day -1 through Day 16
|
Change from baseline 24-hour urinary glucose excretion (UGE)
Délai: Day -1 through 16
|
Day -1 through 16
|
Change from baseline mean fasting plasma glucose
Délai: Day -1 through Day 16
|
Day -1 through Day 16
|
Change from baseline mean morning fasting body weight
Délai: Day -1 through 20
|
Day -1 through 20
|
Renal glucose threshold
Délai: Day -1 through Day 16
|
Day -1 through Day 16
|
Collaborateurs et enquêteurs
C'est ici que vous trouverez les personnes et les organisations impliquées dans cette étude.
Publications et liens utiles
La personne responsable de la saisie des informations sur l'étude fournit volontairement ces publications. Il peut s'agir de tout ce qui concerne l'étude.
Publications générales
- Sha S, Devineni D, Ghosh A, Polidori D, Hompesch M, Arnolds S, Morrow L, Spitzer H, Demarest K, Rothenberg P. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS One. 2014 Sep 30;9(9):e110069. doi: 10.1371/journal.pone.0110069. eCollection 2014.
- Sha S, Devineni D, Ghosh A, Polidori D, Hompesch M, Arnolds S, Morrow L, Spitzer H, Demarest K, Rothenberg P. Pharmacodynamic effects of canagliflozin, a sodium glucose co-transporter 2 inhibitor, from a randomized study in patients with type 2 diabetes. PLoS One. 2014 Aug 28;9(8):e105638. doi: 10.1371/journal.pone.0105638. eCollection 2014. Erratum In: PLoS One. 2014 Sep 30;9(9):e110069.
Dates d'enregistrement des études
Ces dates suivent la progression des dossiers d'étude et des soumissions de résultats sommaires à ClinicalTrials.gov. Les dossiers d'étude et les résultats rapportés sont examinés par la Bibliothèque nationale de médecine (NLM) pour s'assurer qu'ils répondent à des normes de contrôle de qualité spécifiques avant d'être publiés sur le site Web public.
Dates principales de l'étude
Début de l'étude
1 juin 2007
Achèvement primaire (Réel)
1 décembre 2007
Achèvement de l'étude (Réel)
1 décembre 2007
Dates d'inscription aux études
Première soumission
20 août 2009
Première soumission répondant aux critères de contrôle qualité
21 août 2009
Première publication (Estimation)
24 août 2009
Mises à jour des dossiers d'étude
Dernière mise à jour publiée (Estimation)
23 avril 2014
Dernière mise à jour soumise répondant aux critères de contrôle qualité
22 avril 2014
Dernière vérification
1 avril 2014
Plus d'information
Termes liés à cette étude
Mots clés
Termes MeSH pertinents supplémentaires
Autres numéros d'identification d'étude
- CR012451
- 28431754NAP1002 (Autre identifiant: Johnson & Johnson Pharmaceutical Research & Development, L.L.C.)
Ces informations ont été extraites directement du site Web clinicaltrials.gov sans aucune modification. Si vous avez des demandes de modification, de suppression ou de mise à jour des détails de votre étude, veuillez contacter register@clinicaltrials.gov. Dès qu'un changement est mis en œuvre sur clinicaltrials.gov, il sera également mis à jour automatiquement sur notre site Web .
Essais cliniques sur Diabète sucré, Type 2
-
Bnai Zion Medical CenterInconnue
-
Jiangsu HengRui Medicine Co., Ltd.Complété
-
HighTide Biopharma Pty LtdRecrutement
-
Chengdu Brilliant Pharmaceutical Co., Ltd.Pas encore de recrutement
-
Endogenex, Inc.Pas encore de recrutementDiabète sucré, Type 2 | Diabète | Diabète sucré de type 2 | Diabète de type 2 | Diabète de type 2
-
Jeil Pharmaceutical Co., Ltd.Pas encore de recrutementDiabète sucré de type 2Corée, République de
-
Nanjing First Hospital, Nanjing Medical UniversityRecrutement
-
Nanjing First Hospital, Nanjing Medical UniversityRecrutement
-
Xiangya Hospital of Central South UniversityRecrutement
-
Sun Yat-sen UniversityGuangdong Provincial Hospital of Traditional Chinese Medicine; The Third Affiliated... et autres collaborateursRecrutement
Essais cliniques sur JNJ 28431754
-
Johnson & Johnson Pharmaceutical Research & Development...Complété
-
Johnson & Johnson Pharmaceutical Research & Development...Complété
-
Johnson & Johnson Pharmaceutical Research & Development...Complété
-
Johnson & Johnson Pharmaceutical Research & Development...Complété
-
Janssen Research & Development, LLCThe George Institute for Global Health, AustraliaComplétéMaladies cardiovasculaires | Diabète sucré, Type 2 | Facteurs de risqueÉtats-Unis, Australie, Pologne, Ukraine, Royaume-Uni, Belgique, Allemagne, France, Espagne, Argentine, Colombie, Israël, Mexique, Inde, Canada, Pays-Bas, Suède, Malaisie, Nouvelle-Zélande, Estonie, Fédération Russe, Hongrie, Norvège, L... et plus
-
Johnson & Johnson Pharmaceutical Research & Development...Complété
-
Johnson & Johnson Pharmaceutical Research & Development...Complété
-
Johnson & Johnson Pharmaceutical Research & Development...Complété
-
Johnson & Johnson Pharmaceutical Research & Development...Complété
-
Johnson & Johnson Pharmaceutical Research & Development...ComplétéEn bonne santé | Insuffisance rénaleÉtats-Unis